AHL
IBRX icon

Abel Hall LLC’s ImmunityBio IBRX Stock Holding History

Abel Hall LLC’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$98.1K Sell
11,204
-8,609
-43% -$65.2K 0.02% 837
2026
Q1 		$152K Buy
+19,813
New +$136K 0.03% 653

Other funds holding IBRX

DADC
D.A. Davidson & Co Great Falls, Montana $18.1B AUM 24.63% 1-Year Est. Return
SSWM
Sheets Smith Wealth Management Winston-Salem, North Carolina $1B AUM 29.77% 1-Year Est. Return
LCGC
Legacy Capital Group California Los Gatos, California $332M AUM 42.15% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
PL
Plancorp LLC Saint Louis, Missouri $4.1B AUM 25.19% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
MWM
MFG Wealth Management Indianapolis, Indiana $140M AUM 44.72% 1-Year Est. Return
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
RG
Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return

Abel Hall LLC's IBRX Position: Q2 2026 in Review

Abel Hall LLC reduced its ImmunityBio (IBRX) stake by 43% in Q2 2026, selling an estimated $65.2K and leaving 11,204 shares worth $98.1K. The position accounts for 0.02% of the portfolio, ranked #837.

Abel Hall LLC first reported a position in IBRX in Q1 2026 and has held it in 2 quarters since. The position peaked at $152K in Q1 2026. 122 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • Abel Hall LLC held 11,204 shares of ImmunityBio worth $98.1K as of Q2 2026.
  • Abel Hall LLC sold 8,609 ImmunityBio shares in Q2 2026, an estimated $65.2K.
  • ImmunityBio made up 0.02% of Abel Hall LLC's portfolio in Q2 2026, its #837 holding.
  • Abel Hall LLC first reported a position in ImmunityBio in Q1 2026 and has held it in 2 quarters since.
  • Abel Hall LLC's ImmunityBio position peaked at $152K in Q1 2026.
  • 122 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Abel Hall LLC's 13F filing for Q2 2026, filed 24 Jul 2026.